Enrollment required 3 months of active multi-agent chemotherapy, with no progression before IRE treatment. Endpoints were 30- and 90-day mortality from enrollment and the new onset of an adverse event (AE).Results:87 patients were enrolled in the registry between May 2019 and May 2023. Mean ...